These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 18829780)

  • 61. ECGs before stimulants in children.
    Med Lett Drugs Ther; 2008 Jul; 50(1291):60. PubMed ID: 18654112
    [No Abstract]   [Full Text] [Related]  

  • 62. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
    Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
    Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Can you use a sequential sample of patients as a substitute for a full practice audit?: Study of mammography screening rates in 20 family practices in Ontario.
    Swanson G; Kaczorowski J
    Can Fam Physician; 2008 Oct; 54(10):1436-7, 1437.e1-5. PubMed ID: 18854475
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Survey of United States child and adolescent psychiatrists' cardiac screening practices prior to starting patients on stimulants.
    Leslie LK; Rodday AM; Saunders TS; Cohen JT; Wong JB; Sheldrick RC; Parsons SK
    J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):375-84. PubMed ID: 23083024
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Absence of cytogenetic effects in children and adults with attention-deficit/hyperactivity disorder treated with methylphenidate.
    Ponsa I; Ramos-Quiroga JA; Ribasés M; Bosch R; Bielsa A; Ordeig MT; Morell M; Miró R; de Cid R; Estivill X; Casas M; Bayés M; Cormand B; Hervás A
    Mutat Res; 2009 Jun; 666(1-2):44-9. PubMed ID: 19457516
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A case of acute cardiomyopathy and pericarditis associated with methylphenidate.
    Dadfarmay S; Dixon J
    Cardiovasc Toxicol; 2009 Mar; 9(1):49-52. PubMed ID: 19296063
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of imipramine hydrochloride on the EEG of children with Attention-Deficit/Hyperactivity Disorder who are non-responsive to stimulants.
    Clarke AR; Barry RJ; McCarthy R; Selikowitz M; Johnstone SJ
    Int J Psychophysiol; 2008 Jun; 68(3):186-92. PubMed ID: 18304665
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Diagnosis and management of sudden death in children.
    Fish FA; Kannankeril PJ
    Curr Opin Pediatr; 2012 Oct; 24(5):592-602. PubMed ID: 22954955
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Parental alcohol screening in pediatric practices.
    Wilson CR; Harris SK; Sherritt L; Lawrence N; Glotzer D; Shaw JS; Knight JR
    Pediatrics; 2008 Nov; 122(5):e1022-9. PubMed ID: 18977952
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Drugs for attention deficit hyperactivity disorder].
    Montañés-Rada F; Gangoso-Fermoso AB; Martíínez-Granero MA
    Rev Neurol; 2009 May 1-15; 48(9):469-81. PubMed ID: 19396764
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Behavioral health practices in the midst of black box warnings and mental health reform.
    Williams J; Klinepeter K; Palmes G; Pulley A; Meschan Foy J
    Clin Pediatr (Phila); 2007 Jun; 46(5):424-30. PubMed ID: 17556739
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Measurement of growth in stimulant-naive children with attention-deficit/hyperactivity disorder by using cross-sectional and longitudinal approaches.
    Poulton A; Nanan R
    Pediatrics; 2008 Jul; 122(1):221; author reply 221-2. PubMed ID: 18596017
    [No Abstract]   [Full Text] [Related]  

  • 73. Prescribing medications in pediatrics: concerns regarding FDA approval and pharmacokinetics.
    Novak E; Allen PJ
    Pediatr Nurs; 2007; 33(1):64-70. PubMed ID: 17411005
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [The effects of methylphenidate on various components of visual attention in children with attention-deficit hyperactivity disorder].
    Durukan I; Türkbay T; Cöngöloğlu A
    Turk Psikiyatri Derg; 2008; 19(4):358-64. PubMed ID: 19110977
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Response to Calver et al. on the WA regulatory scheme for stimulants.
    Stevens M
    Aust N Z J Public Health; 2008 Apr; 32(2):182. PubMed ID: 18412693
    [No Abstract]   [Full Text] [Related]  

  • 76. Current strategies in the diagnosis and treatment of childhood attention-deficit/hyperactivity disorder.
    Rader R; McCauley L; Callen EC
    Am Fam Physician; 2009 Apr; 79(8):657-65. PubMed ID: 19405409
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Attention-deficit/hyperactivity disorder in children and adolescents: closing diagnostic, communication, and treatment gaps.
    Vierhile A; Robb A; Ryan-Krause P
    J Pediatr Health Care; 2009; 23(1 Suppl):S5-23. PubMed ID: 19084757
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Screening for attention-deficit/hyperactivity disorder in a select sample of injured and uninjured pediatric patients.
    Maxson RT; Lawson KA; Pop R; Yuma-Guerrero P; Johnson KM
    J Pediatr Surg; 2009 Apr; 44(4):743-8. PubMed ID: 19361634
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Reasons for antidepressant prescriptions in Canada.
    Patten SB; Esposito E; Carter B
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):746-52. PubMed ID: 17286318
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Strategic opportunities for effective optimal prescribing and medication management.
    Sketris IS; Langille Ingram EM; Lummis HL
    Can J Clin Pharmacol; 2009; 16(1):e103-25. PubMed ID: 19182305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.